Novartis Vaccines & Diagnostics, Gmbh

Five Prime Therapeutics, Inc.

Xoma Technology Ltd.

Eureka Therapeutics, Inc.

Li Long

Cheng Liu

Arnold H Horwitz

Kirston E Koths

William Michael Kavanaugh

Deborah Lee Zimmerman

Hong Liu

W Michael Kavanaugh

Maria Calderon-Cacia

Gregory Martin Harrowe

Kevin Hestir

Zhiyuan Yang

Thomas Harding

Haishan Lin

Jingwei Lu

Mohammad Luqman

Asha Yabannavar

Sang Hoon Lee

Servando Palencia

Neal Cheng

Deborah Hurst

Isabel Zaror

Bao-lu Chen

Thomas Brennan

Yiyang Xu

Jingyi Xiang

Xiaofeng Lu

Bao-Lu Chen

Mohammed Luqman

Daniel E Lopes De Menezes

Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.

Antibody agents specific for human CD19 and uses thereof

M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.

Humanized M-CSF specific monoclonal antibodies, kits, and uses thereof

Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.

Methods of treating lung cancer

The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising an AFP peptide and an MHC class I protein. Also provided are methods of making and using these constructs.

Constructs targeting AFP peptide/MHC complexes and uses thereof

M-CSF specific monoclonal antibody and uses thereof

M-CSF specific monoclonal antibody and uses therof

Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.

FGFR1 extracellular domain combination therapies for lung cancer

Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.

Antagonist anti-CD40 monoclonal antibodies and methods for their use

Antagonist anti-CD40 antibodies

Methods of using colony stimulating factor receptor (CSF1R) extracellular domain (ECD) fusion molecules for treating osteolytic bone loss, cancer metastasis, cancer metastasis-induced osteolytic bone loss, and tumor growth are provided. CSF1R ECD fusion molecules, polynucleotides encoding CSF1R ECD fusion molecules, and methods of making CSF1R ECD fusion molecules are also provided.

Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules

The present invention relates to specific CSF1R ECD fusion molecules that exhibit improved therapeutic properties. The invention also relates to polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules. The invention also relates to methods of making and using the CSF1R ECD fusion molecules. The invention further relates to methods of treatment using the CSF1R ECD fusion molecules. For example, certain CSF1R ECDs of the invention may be used to treat rheumatoid arthritis (RA) or multiple sclerosis (MS).

Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules

Growing community of inventors

Lafayette, CA, United States of America

Li Long